title: Diagnosis and management of paraneoplastic neurologic disorders.
abstract: Paraneoplastic neurologic disorders (PND) are a heterogeneous group of immune-mediated neurological disorders associated with systemic cancers. When a PND is diagnosed, prompt identification and treatment of the associated tumor is important as PND stabilization and in some cases improvement have been reported after tumor treatment. The cancer, however, may be small and difficult to detect or the onset of the PND may precede the development of the cancer by months or years. In the latter cases, patients often initially present to neurologists or internists who will need assistance from their oncology colleagues to uncover the cancer. It is therefore important to be aware of the associations of common cancers with specific PND syndromes and the significance in some PND of the presence in serum and/or cerebrospinal fluid (CSF) of specific antineuronal antibodies. Together, this information can focus the search for the tumor or support continued vigilance. Previously thought to be poorly responsive to therapies, it is now recognized that there is a subgroup of PND, mostly associated with antibodies to antigens on the neuronal cell surface that are highly treatment responsive. Treatments aimed at the PND are mostly immunosuppressive and include corticosteroids, plasma exchange and intravenous immunoglobulins (IVIg). Immunosuppressive chemotherapeutics and B-cell targeting drugs such as rituximab also may be useful. Although cancer patients tolerate these therapies, there is the risk of increased toxicity when combined with tumor-directed treatments and treatment plans should be coordinated between specialists.
authors.affiliation: Department of Neurology, Hospital Clínic/IDIBAPS, Villarroel, 170, Barcelona, 08036, Spain, mrrosenf@clinic.ub.es.
authors.forename: Myrna R
authors.initials: MR
authors.lastname: Rosenfeld
authors.forename: Josep
authors.initials: J
authors.lastname: Dalmau
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000150:complications; D004347:Drug Interactions; D005260:Female; D005833:Genital Neoplasms, Female / Q000150:complications; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D020361:Paraneoplastic Syndromes, Nervous System / Q000175:diagnosis* / Q000628:therapy*; D010951:Plasma Exchange; D013736:Testicular Neoplasms / Q000150:complications; D013945:Thymoma / Q000150:complications
chemical_list: D000305:Adrenal Cortex Hormones; D000906:Antibodies; D014408:Biomarkers, Tumor; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors
references.citation: J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40
references.pmid: 15258215
references.citation: Arch Neurol. 2010 Sep;67(9):1109-15
references.pmid: 20837856
references.citation: Eur J Neurol. 2011 Nov;18(11):1291-8
references.pmid: 21418441
references.citation: Neurology. 2011 Nov 1;77(18):1698-701
references.pmid: 22013185
references.citation: Clin Nucl Med. 2013 Apr;38(4):241-7
references.pmid: 23429394
references.citation: Cancer Immunol Immunother. 2009 Nov;58(11):1795-800
references.pmid: 19294382
references.citation: Brain. 2004 Aug;127(Pt 8):1831-44
references.pmid: 15215214
references.citation: Brain. 2005 Aug;128(Pt 8):1764-77
references.pmid: 15888538
references.citation: N Engl J Med. 2000 Sep 21;343(12):847-55
references.pmid: 10995864
references.citation: Lancet Neurol. 2013 Feb;12(2):157-65
references.pmid: 23290630
references.citation: Eur J Neurol. 2006 Jul;13(7):682-90
references.pmid: 16834698
references.citation: Ann Neurol. 2003 Mar;53(3):347-53
references.pmid: 12601702
references.citation: J Clin Immunol. 2010 Jan;30(1):106-13
references.pmid: 19838774
references.citation: J Neurooncol. 1998 Nov;40(2):131-6
references.pmid: 9892095
references.citation: Pediatr Blood Cancer. 2009 Dec;53(6):1048-53
references.pmid: 19672966
references.citation: J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):479-82
references.pmid: 10727484
references.citation: Ann Neurol. 2002 May;51(5):625-30
references.pmid: 12112110
references.citation: N Engl J Med. 2000 Jan 6;342(1):21-7
references.pmid: 10620645
references.citation: J Neurol. 2004 Mar;251(3):321-6
references.pmid: 15015013
references.citation: J Immunol. 2005 Dec 1;175(11):7755-62
references.pmid: 16301686
references.citation: J Pediatr. 2013 Apr;162(4):850-856.e2
references.pmid: 23164315
references.citation: Ann Neurol. 2011 Feb;69(2):303-11
references.pmid: 21387375
references.citation: Mayo Clin Proc. 2003 Nov;78(11):1363-8
references.pmid: 14601695
references.citation: J Neurol. 2002 Jun;249(6):745-53
references.pmid: 12111309
references.citation: Ann N Y Acad Sci. 2007 Sep;1110:256-60
references.pmid: 17911440
references.citation: J Neurol. 1997 Feb;244(2):85-9
references.pmid: 9120501
references.citation: Curr Treat Options Neurol. 2010 Jan;12(1):54-63
references.pmid: 20842490
references.citation: J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1341-4
references.pmid: 20667866
references.citation: N Engl J Med. 1999 Jun 10;340(23):1788-95
references.pmid: 10362822
references.citation: Neuro Oncol. 2004 Jan;6(1):55-62
references.pmid: 14769141
references.citation: Lancet Neurol. 2010 Jan;9(1):67-76
references.pmid: 19962348
references.citation: Lancet Neurol. 2010 Aug;9(8):776-85
references.pmid: 20580615
references.citation: Ann Neurol. 2012 Jun;71(6):815-24
references.pmid: 22447725
references.citation: J Neurol. 2006 Jan;253(1):16-20
references.pmid: 16444604
references.citation: Brain. 2001 Jun;124(Pt 6):1138-48
references.pmid: 11353730
references.citation: J Neurol Sci. 1999 Mar 1;163(2):159-62
references.pmid: 10371077
references.citation: Clin Exp Immunol. 2009 Dec;158 Suppl 1:2-13
references.pmid: 19883419
references.citation: Lancet. 2001 Jan 13;357(9250):96-100
references.pmid: 11197446
references.citation: Arch Neurol. 2009 Aug;66(8):1016-20
references.pmid: 19667224
references.citation: J Neurosci. 2010 Apr 28;30(17):5866-75
references.pmid: 20427647
references.citation: Brain. 2001 Feb;124(Pt 2):437-43
references.pmid: 11157570
references.citation: J Neuroimmunol. 1997 Apr;74(1-2):55-61
references.pmid: 9119979
references.citation: Mol Imaging Biol. 2008 May-Jun;10(3):131-7
references.pmid: 18297363
references.citation: Arch Ophthalmol. 2009 Apr;127(4):390-7
references.pmid: 19365013
references.citation: Neurologist. 2007 Sep;13(5):261-71
references.pmid: 17848866
references.citation: J Peripher Nerv Syst. 2010 Dec;15(4):302-6
references.pmid: 21199101
references.citation: Lancet Neurol. 2008 Dec;7(12):1091-8
references.pmid: 18851928
references.citation: Arch Dis Child. 2012 May;97(5):461-3
references.pmid: 21460401
references.citation: Curr Treat Options Neurol. 2013 Apr;15(2):224-39
references.pmid: 23263888
references.citation: Ann Neurol. 2009 Apr;65(4):424-34
references.pmid: 19338055
references.citation: J Neurol. 2010 Apr;257(4):509-17
references.pmid: 20035430